These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 31545377)

  • 1. Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine Tumor.
    Lamberti G; Faggiano A; Brighi N; Tafuto S; Ibrahim T; Brizzi MP; Pusceddu S; Albertelli M; Massironi S; Panzuto F; Badalamenti G; Riccardi F; Butturini G; Gelsomino F; De Divitiis C; Modica R; Bongiovanni A; La Salvia A; Torchio M; Colao A; Ferone D; Campana D
    J Clin Endocrinol Metab; 2020 Jan; 105(1):. PubMed ID: 31545377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing Somatostatin Analogs in the Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors.
    Allaw MB; Switchenko JM; Khalil L; Wu C; Alese OB; Akce M; Draper A; Jones AT; El-Rayes B; Shaib W
    Oncology; 2022; 100(3):131-139. PubMed ID: 35078191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes of patients with G1/G2 neuroendocrine tumors arising from foregut or hindgut treated with somatostatin analogs: a retrospective study.
    Ida H; Honma Y; Hirano H; Shoji H; Iwasa S; Okita N; Takashima A; Kato K; Fukuda T; Boku N
    Invest New Drugs; 2019 Jun; 37(3):573-578. PubMed ID: 30267338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study.
    Carmona-Bayonas A; Jiménez-Fonseca P; Lamarca Á; Barriuso J; Castaño Á; Benavent M; Alonso V; Riesco-Martínez MDC; Alonso-Gordoa T; Custodio A; Sánchez Cánovas M; Hernando Cubero J; López C; Lacasta A; Fernández Montes A; Marazuela M; Crespo G; Escudero P; Diaz JÁ; Feliciangeli E; Gallego J; Llanos M; Segura Á; Vilardell F; Percovich JC; Grande E; Capdevila J; Valle JW; García-Carbonero R
    J Clin Oncol; 2019 Oct; 37(28):2571-2580. PubMed ID: 31390276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiproliferative Effect of Above-Label Doses of Somatostatin Analogs for the Management of Gastroenteropancreatic Neuroendocrine Tumors.
    Diamantopoulos LN; Laskaratos FM; Kalligeros M; Shah R; Navalkissoor S; Gnanasegaran G; Banks J; Smith J; Jacobs B; Galanopoulos M; Mandair D; Caplin M; Toumpanakis C
    Neuroendocrinology; 2021; 111(7):650-659. PubMed ID: 32541155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic sequences in patients with grade 1-2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group.
    Faggiano A; Di Maio S; Mocerino C; Ottaviano M; De Divitiis C; Guarnotta V; Dolce P; Modica R; Puliafito I; Tozzi L; Di Sarno A; Leo S; Riccardi F; Palmieri G; Tafuto S; Bianco A; Badalamenti G; Colao A;
    Endocrine; 2019 Nov; 66(2):417-424. PubMed ID: 30875056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating Transcript Analysis (NETest) in GEP-NETs Treated With Somatostatin Analogs Defines Therapy.
    Ćwikła JB; Bodei L; Kolasinska-Ćwikła A; Sankowski A; Modlin IM; Kidd M
    J Clin Endocrinol Metab; 2015 Nov; 100(11):E1437-45. PubMed ID: 26348352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study.
    Jimenez-Fonseca P; Carmona-Bayonas A; Lamarca A; Barriuso J; Castaño A; Benavent M; Alonso V; Riesco MDC; Alonso-Gordoa T; Custodio A; Sanchez Canovas M; Hernando J; López C; La Casta A; Fernandez Montes A; Marazuela M; Crespo G; Diaz JA; Feliciangeli E; Gallego J; Llanos M; Segura A; Vilardell F; Percovich JC; Grande E; Capdevila J; Valle J; Garcia-Carbonero R
    Neuroendocrinology; 2022; 112(1):88-100. PubMed ID: 33508849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined Lanreotide Autogel and Temozolomide Treatment of Progressive Pancreatic and Intestinal Neuroendocrine Tumors: The Phase II SONNET Study.
    Pavel M; Lahner H; Hörsch D; Rinke A; Denecke T; Koch A; Regnault B; Helbig D; Hoffmanns P; Raderer M
    Oncologist; 2024 May; 29(5):e643-e654. PubMed ID: 38206830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatostatin analogues according to Ki67 index in neuroendocrine tumours: an observational retrospective-prospective analysis from real life.
    Faggiano A; Carratù AC; Guadagno E; Tafuto S; Tatangelo F; Riccardi F; Mocerino C; Palmieri G; Damiano V; Siciliano R; Leo S; Mauro A; Tozzi LF; Battista C; De Rosa G; Colao A
    Oncotarget; 2016 Feb; 7(5):5538-47. PubMed ID: 26701729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing Somatostatin Analog Use in Well or Moderately Differentiated Gastroenteropancreatic Neuroendocrine Tumors.
    Carmona-Bayonas A; Jiménez-Fonseca P; Custodio A; Grande E; Capdevila J; López C; Teule A; Garcia-Carbonero R;
    Curr Oncol Rep; 2017 Sep; 19(11):72. PubMed ID: 28920153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors.
    Cives M; Kunz PL; Morse B; Coppola D; Schell MJ; Campos T; Nguyen PT; Nandoskar P; Khandelwal V; Strosberg JR
    Endocr Relat Cancer; 2015 Feb; 22(1):1-9. PubMed ID: 25376618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of controversial gastroenteropancreatic neuroendocrine tumour clinical situations with somatostatin analogues: results of a Delphi questionnaire panel from the NETPraxis program.
    Sevilla I; Segura Á; Capdevila J; López C; García-Carbonero R; Grande E;
    BMC Cancer; 2016 Nov; 16(1):858. PubMed ID: 27821081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When Ki-67 Is ≥10%?
    Merola E; Alonso Gordoa T; Zhang P; Al-Toubah T; Pellè E; Kolasińska-Ćwikła A; Zandee W; Laskaratos F; de Mestier L; Lamarca A; Hernando J; Cwikla J; Strosberg J; de Herder W; Caplin M; Cives M; van Leeuwaarde R
    Oncologist; 2021 Apr; 26(4):294-301. PubMed ID: 33301235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PRRT genomic signature in blood for prediction of
    Bodei L; Kidd MS; Singh A; van der Zwan WA; Severi S; Drozdov IA; Cwikla J; Baum RP; Kwekkeboom DJ; Paganelli G; Krenning EP; Modlin IM
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(7):1155-1169. PubMed ID: 29484451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Antiproliferative Effect of Somatostatin Analogs -  Data Analyses and Clinical Applications in the Context of the CLARINET Study].
    Bencsiková B
    Klin Onkol; 2016; 29(4):253-8. PubMed ID: 27534781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression of somatostatin receptor 4 predicts clinical outcome of patients with metastatic neuroendocrine tumors treated with somatostatin analogs.
    Slaby O; Sachlova M; Bednarikova M; Fabian P; Svoboda M; Vytopilova S; Valik D; Vyzula R
    Cancer Biother Radiopharm; 2010 Apr; 25(2):237-43. PubMed ID: 20423238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does combination of "cold" and "hot" somatostatin analogs prolong survival of patients with neuroendocrine neoplasms?
    Sowa-Staszczak A; Stefanska A; Chrapczynski P; Trofimiuk-Müldner M; Szura M; Hubalewska-Dydejczyk A
    Endocr J; 2017 Feb; 64(2):171-177. PubMed ID: 27853048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-acting somatostatin analogs and well differentiated neuroendocrine tumors: a 20-year-old story.
    Faggiano A
    J Endocrinol Invest; 2024 Jan; 47(1):35-46. PubMed ID: 37581846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide.
    Ricci S; Antonuzzo A; Galli L; Ferdeghini M; Bodei L; Orlandini C; Conte PF
    Ann Oncol; 2000 Sep; 11(9):1127-30. PubMed ID: 11061606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.